<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="14328"><DrugName>LHM-123</DrugName><DrugSynonyms><Name><Value>LHM-123</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Alzheimers disease therapy, APPI</Value></Name><Name><Value>MAALZ program (Alzheimers disease), Mazal Plant Pharmaceuticals</Value></Name></DrugSynonyms><CompanyOriginator id="23400">Advanced Plant Pharmaceuticals Inc</CompanyOriginator><CompaniesSecondary><Company id="1011257">Mazal Plant Pharmaceuticals Inc</Company><Company id="23400">Advanced Plant Pharmaceuticals Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1011257" type="Company"><TargetEntity id="4297198012" type="organizationId">Mazal Plant Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="23400" type="Company"><TargetEntity id="4295900518" type="organizationId">World Health Energy Holdings Inc</TargetEntity></SourceEntity><SourceEntity id="14" type="ciIndication"><TargetEntity id="G30" type="ICD10"></TargetEntity><TargetEntity id="331.0" type="ICD9"></TargetEntity><TargetEntity id="10012271" type="MEDDRA"></TargetEntity><TargetEntity id="D000544" type="MeSH"></TargetEntity><TargetEntity id="-1268969445" type="omicsDisease"></TargetEntity><TargetEntity id="101" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="14">Alzheimers disease</Indication></IndicationsSecondary><ActionsSecondary><Action id="59620">Unspecified drug target</Action><Action id="1615">Neuroprotectant</Action></ActionsSecondary><Technologies><Technology id="1647">Natural product</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2017-08-21T10:08:37.000Z</LastModificationDate><ChangeDateLast>2011-01-04T07:52:44.000Z</ChangeDateLast><AddedDate>1997-01-16T18:20:13.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="1011257" linkType="Company"&gt;Mazal Plant Pharmaceuticals&lt;/ulink&gt;  was investigating the plant-derived product, LHM-123, after   acquiring  the drug from its former parent company  &lt;ulink linkID="23400" linkType="Company"&gt;Advanced Plant  Pharmaceuticals&lt;/ulink&gt;  (APPI),  for the potential treatment for Alzheimer's disease [&lt;ulink linkID="229962" linkType="reference"&gt;229962&lt;/ulink&gt;]. Preclinical development was ongoing in December 2004 [&lt;ulink linkID="573760" linkType="Reference"&gt;573760&lt;/ulink&gt;]. By July 2008, the company had a program called MAALZ listed on its pipeline, of which LHM-123   was presumed to be a part of [&lt;ulink linkID="924961" linkType="Reference"&gt;924961&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In December 2004, Mazal received all the rights to LHM-123 from its parent company APPI [&lt;ulink linkID="573760" linkType="Reference"&gt;573760&lt;/ulink&gt;]; however, in July 2005, APPI sold Mazal to Akid Corp [&lt;ulink linkID="613336" linkType="Reference"&gt;613336&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In January 1997,  APPI filed a patent application for LHM-123 in the US, following in vitro results showed the drug destroyed cancer cells and case studies in which volunteers had greatly improved white blood cell counts [&lt;ulink linkID="229638" linkType="reference"&gt;229638&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="23400">Advanced Plant Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="14">Alzheimers disease</Indication><StatusDate>2004-12-01T00:00:00.000Z</StatusDate><Source id="573760" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1011257">Mazal Plant Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate>2011-01-04T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="23400">Advanced Plant Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate>1996-12-20T00:00:00.000Z</StatusDate><Source id="229058" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1011257">Mazal Plant Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate>2004-12-01T00:00:00.000Z</StatusDate><Source id="573760" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1011257">Mazal Plant Pharmaceuticals Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="23400">Advanced Plant Pharmaceuticals Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="20">Company - M&amp;A (in whole or part)</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="109528" title="Mazal Plant Pharmaceuticals to obtain Advanced Plant Pharmaceuticals's MAHDL-01, Leuknil and LHM-123 "/></Deals><PatentFamilies><PatentFamily id="1168153" number="WO-09418993" title="Therapeutic Herbal Composition"/><PatentFamily id="354063" number="WO-09418994" title="Therapeutic Herbal Composition"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><hasSWOTs>N</hasSWOTs></drugRecordOutput>